TMC589337

· Tibotec Pharmaceuticals, Ireland

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TMC589337, covering 2016-10-28 to 2016-10-28. Get the full timeline:

Most recent: Clinical Trial Update: PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354. [Phase 1]

See pricing